Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its ...

Core Viewpoint - Karolinska Development AB has divested its remaining shares in OssDsign, resulting in a capital injection of approximately SEK 34.5 million, which strengthens the company's liquidity and allows for prioritization of other investments with greater value creation potential [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying breakthrough medical innovations in the Nordic region, investing in the creation and growth of companies that advance these innovations into commercial products [4][5]. - The company has access to world-class medical innovations from the Karolinska Institutet and other leading universities and research institutes in the Nordic region, aiming to build companies around leading scientists supported by experienced management teams [5][6]. Investment Strategy - The divestment from OssDsign reflects a strategic decision to realize profits and enhance the financial position of Karolinska Development, enabling the company to invest in other holdings with higher potential returns [2][3]. - Following the divestment, Karolinska Development has no direct ownership in OssDsign but retains indirect ownership through the KCIF Co-Investment Fund [3]. Portfolio and Management - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for life-threatening or serious debilitating diseases, led by an entrepreneurial team of investment professionals with a proven track record [6].

[Music] the uh center of the action of our research of development organization which is the lifeblood of a company like Johnson and Johnson. So here we have about 2500 scientists and researchers that are connected with the rest of our R&D organization. Duatau is chairman and CEO of Johnson and Johnson, one of the largest drug makers in the world.We met with him at his firm's research center to learn how a major pharmaceutical company develops cuttingedge drugs. It started with a smaller campus and graduall ...

Sanara MedTech Investor Presentation Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," "we," "our" or "us"). All statements other than statements of historical fact contained herein are forward-looking statements. These statements may be identified by terms such as "aims," "anticipates," "believes," "c ...

Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution Fleurieux-sur-l’Arbresle - France - June 5, 2025 at 6 p.m. Safe Group, a leading player in the field of medical devices for spine surgery, is pleased to announce that Frida, the innovative cervical plate developed by SpineUp, has received 510(k) clearance from the Food and Drug Administration (FDA). This clearance marks a crucial step in SpineUp's expansion into the North American market, and testifies to its ongoing commitment to provid ...

来源：新华网 中国医院协会常务副会长毛群安对"首都国际医学大会"进行了重点推介。本次大会以"开放、合作、共 建、共享"为主题，设有主论坛及六场平行分论坛，涵盖医学创新、全民健康覆盖、临床研究、医防融 合等议题，推动"政策-技术-服务"全链条对话，促进中外卫生健康交流合作，促进跨界融合交流，共同 推动医学科技创新，鼓励和支持创新成果应用，让群众享受更加公平可及、全生命周期的健康服务。 本届服贸会继续围绕"全球服务、互惠共享"的永久主题，结合2025年服务贸易数字化和智能化发展新趋 势，设置年度主题"数智领航，服贸焕新"。继续设置以健康卫生服务为代表的9个专题，重点展示数字 技术、人工智能等新技术在服务贸易领域的应用，不断促进服务业扩大开放和服务贸易高质量发展。 中国医院 协会常务副会长毛群安发言。新华网 毕尚宏摄 活动现 场。新华网 毕尚宏摄 新华网北京6月8日电（毕尚宏）2025年中国国际服务贸易交易会（以下简称"服贸会"）健康卫生服务专 题推介暨首都国际医学大会启动会6月8日在国家会议中心召开。 据介绍，2025年服贸会健康卫生服务专题将于9月10日至14日在首钢园举行，专题将在二号馆设置"智疗 云枢前瞻矩 ...

ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. Penumbra Introduces the Ruby® XL System – the Longest, Largest, and Sof ...

Penumbra (PEN) 2025 Conference June 04, 2025 09:55 AM ET Speaker0 Okay. So we're ready to kick off. This is the fireside chat with Penumbra. My name is Mike Sarcone. I'm one of the analysts on the US medical supplies and devices team. And with us from the company today, we have Adam El Seltzer. He's co founder, president, chairman, and CEO. We've also got Jason Mills, director of strategy. And Cecilia Furlong, who is a director of business Development, is also here with us. So team, thank you for joining us ...

Establishment Labs Holdings (ESTA) 2025 Conference June 04, 2025 07:35 AM ET Speaker0 Good morning, everybody. Thanks for joining us here for our first session in the med tech track. I'm Matt Taylor, the US medical supplies and devices analyst here at Jefferies. And I'm joined by the management team on my left here for Establishment Labs. So we have Pete Caldini, who's the CEO, and Raj Denhoy, the CFO. And we'll have about a half hour for moderated q and a. So I always like to start high level, especially f ...

Johnson & Johnson (JNJ) FY 2025 Conference May 28, 2025 09:00 AM ET Speaker0 Alright. Thank you, everybody. Thanks, guys. I'm Lee Hambrite, US med tech analyst at Bernstein, and we are thrilled to host Johnson and Johnson. We have chairman and CEO, Joaquin Guato, and CFO, Joe Wall. Guys, for being here. Speaker1 Thank you. Thanks for having us. Speaker0 So we're scheduled for a fifty minute fireside chat. Just a reminder that investors can submit questions at any time through Pigeonhole, and we'll try to wo ...